A team of experts led by IBEC research associate Jordi Alacaraz have discovered how lung adenocarcinoma recruits cancer-associated fibroblasts, and the impact this phenomenon has on the spread of the tumour and the generation of metastases. The results have shown that these cells have a migratory advantage in early stages of the tumour. In the research, they also tested the inhibitor drug Trametinib, which proved to be suitable for eliminating this early migratory movement.
![Article la vanguardia](https://ibecbarcelona.eu/wp-content/uploads/2023/07/Captura.png)
You can read the news at: